



IMPORTANT NOTICE

Route to:
<input type="checkbox"/> Office Manager
<input type="checkbox"/> Medical Staff
<input type="checkbox"/> Nursing Staff
<input type="checkbox"/> Immunization Coordinator

An Immunization Update from the Idaho Immunization Program (IIP)

ROTARIX® TEMPORARY SUSPENSION

The Centers for Disease Control and Prevention (CDC) announced Monday, March 22, 2010, that the FDA has recommended clinicians and public health professionals in the United States to temporarily suspend the use of Rotarix® (GlaxoSmithKline Rotavirus vaccine, NDC 58160-0805-11). The Idaho Immunization Program (IIP) **has not purchased and/or supplied Rotarix** since it came onto the market in 2008. The IIP purchases and supplies RotaTeq vaccine which is not affected by this recommendation.

If your facility privately purchased Rotarix the recommendation is to neither administer nor discard the vaccine, but to store it appropriately until further notice. The FDA is expected to convene an advisory committee, within the next four to six weeks, review the available data and make recommendations on the licensed rotavirus vaccines. Because an updated recommendation from FDA is expected in four to six weeks, clinicians should keep Rotarix for possible future use.

Additional information can be found at:

<http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm205539.htm>

VACCINE SUPPLY

Varicella (VARIVAX®): Due to a change in Merck's ordering system, there will be **no VARIVAX®** (Varicella) orders processed until **April 5, 2010**. Merck plans to be back to normal shipping by Monday, April 12, 2010.

EIPV (IPOL®): Effective immediately, Sanofi Pasteur will only supply IPOL® in the vial presentation. The return of the syringe presentation is not anticipated until late next year (at the earliest).

VACCINE UPDATE

PCV13 (Pevnar 13®): PCV13 is now available from the IIP. Any orders placed for Pevnar® will be filled with PCV13. After your office has received PCV13, please request a return label from the IIP, to return any unused PCV7.

A simplified recommended schedule for administering doses of PCV13 among children who have not previously received PCV7 or PCV13, those incomplete with PCV7 or PCV13 for their age, and the supplemental PCV13 immunization is attached (Attachment One). The entire ACIP document is located at <http://www.cdc.gov/vaccines/programs/vfc/downloads/resolutions/0210-pneumo-508.pdf>

Continue to use the current PCV7 Vaccine Information Statement, and account for Pevnar 13® just like Pevnar® (on ordering form, accountability, etc). PCV13 is listed separately from PCV7 in the Idaho Reminder Information System (IRIS).

March 29, 2010



IMPORTANT NOTICE

An Immunization Update from the Idaho Immunization Program (IIP)

VACCINE UPDATE CONTINUED...

Hib (*Haemophilus Influenza* Type B): All Hib vaccine brands/presentations are available to order from the IIP. Please recall all children who are in need of the booster dose and who have not yet reached their fifth birthday.

A simplified Hib (*Haemophilus Influenza* Type B) vaccine catch-up schedule is attached (Attachment Two).

PROVIDER SURVEY

All VFC providers need to complete a quick, on-line survey beginning Wednesday, March 31, 2010, to be completed by **Friday, April 9, 2010** by close of business. The survey is located on the IIP website on the Healthcare Providers page.

This information will be important in determining vaccine ordering schedules and for 2010 – 2011 influenza planning.

IMMUNIZATION PROGRAM OFFICE CLOSURES

Due to the Governor's budget holdbacks the Idaho Department of Health & Welfare, which includes the IIP, will be closed the following Fridays.

April 2, 2010
April 16, 2010

April 30, 2010
May 14, 2010

May 28, 2010
June 11, 2010

March 29, 2010

Recommended Pneumococcal Conjugate Vaccine Schedule and Dosage Intervals

Recommended schedules for administering doses of PCV13 among children who have not previously received PCV7 or PCV13, those incompletely vaccinated with PCV7 or PCV13 for age, and supplemental PCV13 immunization:

AGE AT EXAMINATION IN MONTHS (MOS.)	VACCINATION HISTORY: TOTAL NUMBER OF PCV7 AND/OR PCV13 DOSES PREVIOUSLY RECEIVED	RECOMMENDED PCV13 REGIMEN ¹
2 – 6 mos.	0 doses	3 doses, 8 weeks apart; fourth dose at age 12-15 mos.
	1 dose	2 doses, 8 weeks apart; fourth dose at age 12-15 mos.
	2 doses	1 dose, 8 weeks after the most recent dose; fourth dose at age 12-15 mos.
7 – 11 mos.	0 doses	2 doses, 8 weeks apart; third dose at age 12-15 mos.
	1 or 2 doses before age 7 mos.	1 dose at age 7-11 mos. with a second dose at 12-15 mos. (\geq 8 weeks later)
12 – 23 mos.	0 doses	2 doses, \geq 8 weeks apart
	1 dose before age 12 mos.	2 doses, \geq 8 weeks apart
	1 dose at \geq 12 mos.	1 dose, \geq 8 weeks after the most recent dose ²
	2 or 3 doses before age 12 mos.	1 dose, \geq 8 weeks after the most recent dose ²
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, \geq 8 weeks after the most recent dose*
24 – 59 mos. Healthy children	Any incomplete schedule	1 dose, \geq 8 weeks after the most recent dose ²
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, \geq 8 weeks after the most recent dose*
24 – 71 mos. Children at high risk ³	Any incomplete schedule of \leq 2 doses	2 doses, one \geq 8 weeks after the most recent dose and another dose \geq 8 weeks later
	Any incomplete schedule of 3 doses	1 dose, \geq 8 weeks after the most recent dose
	4 doses of PCV7 or other age-appropriate complete PCV7 schedule	1 supplemental dose, \geq 8 weeks after the most recent dose*

Footnotes:

- 1) Minimum interval between doses is 8 weeks except for children vaccinated at age <1 year, for whom minimum interval between doses is 4 weeks.
- 2) No additional PCV13 doses are indicated for children 12 through 23 months of age who have received 2 or 3 doses of PCV7 before age 12 months and at least 1 dose of PCV13 at age 12 months or older.
- 3) For children with underlying medical conditions, PCV13 is indicated through 71 months of age.

* A single supplemental dose of PCV13 given at least 8 weeks after the last dose of PCV7 is recommended for all children 14 through 59 months of age who have received 4 doses of PCV7 or other age-appropriate, complete PCV7 schedule (fully vaccinated with PCV7). For children who have underlying medical conditions, a supplemental dose is recommended through 71 months of age.

Children 6 through 18 years of age: A single dose of PCV 13 may be administered for children 6 through 18 years of age who are at increased risk for invasive pneumococcal disease because of sickle cell disease, HIV-infection, or other immunocompromising condition, regardless of whether they have previously received PCV7 or PPSV23.

The Simplified Hib (*Haemophilus Influenza* Type B) Vaccine Catch-up Schedule

Recommended schedule for health children 7 months – 59 months¹

AGE AT EXAMINATION IN MONTHS (MOS.)	VACCINATION HISTORY: TOTAL NUMBER OF HIB DOSES PREVIOUSLY RECEIVED	WHEN WAS THE LAST HIB-CONTAINING DOSE RECEIVED	HIB NEEDED TODAY ^{2, 3?}	MINIMUM INTERVAL TO NEXT DOSE OR MINIMUM AGE
7 – 11 mos.	0 doses	Not Received	Yes	4 weeks
	1 dose	1 st dose received \geq 2 months ago	Yes	4 weeks
	2 doses	Both dose 1 and 2 were PedvaxHib [®]	Not today	Age 1 year ⁴
		Dose 1 and 2 were different brands (e.g. one was PedvaxHib [®] and one was ActHIB [®])	Yes ⁵	Age 1 year ⁴
3 doses	Up-to-Date	Not today	Age 1 year ⁴	
12 – 14 mos.	0 doses	Not Received	Yes	8 weeks
	1 dose	1 st dose received $<$ 12 mos. of age	Yes ⁵	8 weeks
		1 st dose received \geq 12 mos. of age	Yes ⁴	Complete ⁶
	2 doses	1 st dose received $<$ 12 mos. of age, 2 nd dose \geq 12 mos. of age	Yes	Complete ⁶
		1 st and 2 nd dose received \geq 12 mos. of age	No ⁶	Complete ⁶
		2 nd dose received $<$ 12 mos. of age	Yes ⁴	Complete ⁶
	3 doses	3 rd dose received \geq 12 mos. of age	No ⁶	Complete ⁶
3 rd dose received $<$ 12 mos. of age		Yes ⁴	Complete ⁶	
15 – 59 mos.	0 doses	Not Received	Yes	Complete ⁶
	1 dose	1 st dose received \geq 15 mos. of age	No ⁶	Complete ⁶
		1 st dose received $<$ 15 mos. of age	Yes ⁴	Complete ⁶
	2 doses	2 nd dose received \geq 15 mos. of age	No ⁶	Complete ⁶
		1 st dose received \geq 12 mos. of age	No ⁶	Complete ⁶
		1 st dose received $<$ 12 mos. of age, 2 nd dose received $<$ 15 mos. of age	Yes ⁴	Complete ⁶
	3 doses	3 rd dose received \geq 12 mos. of age	No ⁶	Complete ⁶
		3 rd dose received $<$ 12 mos. of age	Yes	Complete ⁶

Footnotes:

- 1) This schedule should only be followed for children who are health and do not fall into high-risk categories for Hib disease. HIGH RISK includes children who are American Indian, Alaskan Native, or who have sickle cell disease, leukemia, functional or anatomic asplenia, immunosuppression from cancer chemotherapy, HIV infection, and hematopoietic stem cell transplants (HSCT).
- 2) The Centers for Disease Control and Prevention Catch-Up Schedule is available at: http://www.cdc.gov/vaccines/recs/schedules/downloads/child/2010/10_catchup-schedule-pr.pdf
- 3) Minimum spacing rules can be found at <http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/A/age-interval-table.pdf>.
- 4) If it has been at least 8 weeks since the previous Hib dose.
- 5) If it has been at least 4 weeks since the previous Hib dose.
- 6) Child is complete if the interval between the next to the last and final dose is at least 8 weeks.